—

—

Motalen creates mobile applications in order to disseminate internally engineered advanced technologies via the most wide spread consumer distribution network, App Stores. A large base of users around a franchised, internally developed IP exists with Infernus. The team has focused towards an engineering route with Brain-Computer-Interface to be a first mover and leverage an infrastructure that has been cultivated for over 1.5 years to get to the mass market. Motalen is looking to scale and gain interested entities that have valuable, highly relevant connections in order to continue developing highly valuable IP while growing its app footprint.

—

Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.

Singularis Lab is a high-technology company working in the areas of software development (desktop, mobile, server, and Web), simulation and high-performance computing, computer vision and augmented reality, robotics, and artificial intelligence. The mainline of Singularis Lab activity is software development. Singularis Lab creates effective and high-quality software and information solutions.

—

Micromillennium Information Systems is a software solutions that provided a tool to import old data to the system based on EDI standards. It was founded in 1998 and is located in Sri Lanka.